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in the Factor VII Promoter
By Josephine A. Carew, Eleanor S. Pollak, Katherine A. High, and Kenneth A. Bauer
We have identified a point mutation in the promoter of the
factor VII gene responsible for a severe bleeding disorder in a
patient from a large French-Canadian family with known
consanguinity. The proband has an extremely low plasma
level of factor VII antigen and factor VII coagulant activity
(,1 percent of normal) and suffers from hemarthroses and
chronic arthropathy. Sequencing of the patient’s factor VII 58
flanking region, intron/exon junctions, and coding regions
showed a homozygous point mutation,aCt oGtransversion
at position 294 relative to the translation start site. We show
here that this mutation prevented binding of transcription
factor Sp1 and of other nuclear proteins to this region of the
factor VII promoter and resulted in a 20-fold reduction in
reporter gene expression in HepG2 cells. These data under-
score the importance of this region of the factor VII promoter
for in vivo expression of the factor VII gene.
r 1998 by The American Society of Hematology.
H
UMAN COAGULATION factor VII is a 406 amino acid,
vitamin-K–dependent glycoprotein that is synthesized in
the liver and circulates in blood as an inactive zymogen.1,2
Factor VII, in its activated form (factor VIIa), participates in the
initiation of coagulation via the extrinsic pathway in association
with tissue factor, an integral membrane protein that is exposed
to the circulation upon vascular injury or stimulation of
monocytes and endothelial cells.3-5 The factor VIIa–tissue
factor complex initiates coagulation by activating both factor IX
and factor X, leading to the localized generation of thrombin.6,7
A reduced plasma level of factor VII coagulant activity
(VII:C) leads to factor VII deﬁciency, a bleeding diathesis of
variable severity. It is inherited as an autosomal recessive
disorder, and its incidence is estimated to be 1 per 500,000 in
the general population.8,9 In recent years, at least 30 different
mutations in the factor VII structural gene have been identiﬁed
in patients with factor VII deﬁciency.10-15Although the majority
of the mutations described are missense mutations, several
nonsense mutations, small deletions, and splice site abnormali-
ties have been identiﬁed as well.
Recognition of defects in the promoter of the human factor
VII gene has also become possible with the identiﬁcation and
analysis of its 58 regulatory region by several groups.16-18
Unlike the promoters of many eukaryotic genes, that of the
factor VII gene has neither a CAAT nor a TATA box. However,
it does include binding sites for both ubiquitously distributed
and liver-enriched transcription factors upstream of the major
transcriptional start site at position 251 (all numbering is with
respect to the translational start site at position 11.) Among
these, the sites for Sp1, a ubiquitous transcription factor of the
zinc-ﬁnger family, and for hepatocyte nuclear factor-4 (HNF-4),
a tissue-restricted orphan receptor, were shown to be important
for expression of the factor VII gene.17,18
In contrast to the large number of mutations identiﬁed within
the structural factorVII gene, there are few reports of alterations
within regulatory regions that inﬂuence its expression. We have
recently identiﬁed and characterized a point mutation within the
58 regulatory region of the factor VII gene of a patient with
severe factor VII deﬁciency.19 This mutation is a T to G
substitution at position 261 that markedly reduces promoter
activity by preventing HNF-4 binding and transactivation. In
addition, there is a polymorphism in the 58 regulatory region, a
decanucleotide insertion at position 2323, which is associated
with modest reductions in plasma levels of factor VII antigen
(VII:Ag) and VII:C.20,21 Although the decanucleotide insert is
often found in allelic association with the Arg353Gln substitu-
tion, a polymorphism within exon 8, which itself reduces
plasma levels of VII:Ag and VII:C,22 in vitro analysis of the
insert alone indicated that it causes an approximately 33%
reduction in factor VII promoter activity in human hepatoma cells.18
In this report, we describe a new mutation in the factor VII
promoter that is responsible for factor VII deﬁciency in a large
French-Canadian kindred with known consanguinity.The muta-
tion,aCt oGtransversion at position 294, is within the core
binding site of transcription factor Sp1. It disrupted binding of
both Sp1 and other nuclear proteins to the factor VII promoter,
thereby severely compromising the expression of the factor VII
gene in reporter gene assays.
MATERIALS AND METHODS
Clinical history. The patient is a member of a large kindred from a
small town in Quebec province. Members of his extended family have
been described previously in the medical literature. Two sisters with
factor VII deﬁciency identiﬁed in 1955,23 shortly after the original
description of the disorder,24 were found in 1971 to be related to 11
additional individuals (eight women and three men) with factor VII
deﬁciency.25These 13 patients exhibited plasma levels ofVII:C ranging
from 1.5% to 6% of normal with variable severities of bleeding. The
female patients experienced menorrhagia; several patients had postsur-
gical hemorrhage, bruising, and epistaxis; and one patient suffered a
cerebral hemorrhage. The parents of affected individuals were them-
selves free of clinical symptoms but had plasma levels of VII:Ag and
VII:C that were approximately 50% of normal, suggesting that the trait
was inherited in an autosomal recessive manner. All 13 patients were
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end of the 17th century. Although the incidence of severe factor VII
deﬁciency is quite rare, it was calculated to be approximately 1 in 335
individuals in the descendants of this French couple.25
Informed consent was obtained from the patient and his family. This
study was approved by the Human Studies Committee of the Brockton-
West Roxbury Department of VeteransAffairs Medical Center.
Factor VII assays. Plasma levels of VII:C and VII:Ag were
measured on citrated plasma with a one-stage clotting assay using
Automated Simplastin (Organon Teknika Corp, Durham, NC) and an
enzyme-linked immunoabsorbent assay (American Bioproducts Co,
Parsippany, NJ), respectively. The levels of VII:Ag and VII:C were
expressed as a percentage of the level in a normal pool constructed from
equal volumes of plasma from 30 healthy individuals.
DNA isolation and polymerase chain reaction (PCR). Genomic
DNA was puriﬁed from leukocytes isolated from whole blood of the
patient and his parents by standard methods.26 The immediate 58
ﬂanking region of the factor VII promoter (spanning nucleotides 2404
to 198) was ampliﬁed by PCR and subcloned into the vector pT7blue
(Novagen, Madison,WI) for sequencing.The inserts were sequenced on
a 373A DNA Sequencer (Applied Biosystems, Foster City, CA) by the
dideoxy chain termination method.27 A clone carrying the patient’s
mutation provided the template for the subsequent PCR reaction
spanning nucleotides 2185 to 11 (with base 11 designated as the
translational start site), which was subcloned into the promoterless
pOGH reporter plasmid containing the human growth hormone struc-
tural gene (Nichols Diagnostics Institute, San Juan Capistrano, CA); the
presence of the mutation was conﬁrmed by sequencing. A plasmid
containing the wild-type sequence of the 2185 to 11 fragment of the
factor VII promoter was prepared similarly and used as a positive
control. The exons of the factor VII gene were ampliﬁed by PCR from
the patient’s genomic DNA as described previously.12 The PCR
reactions of exons 1a, 5, 7, and 8 were then subcloned and sequenced,
whereas those of exons 2, 3, 4, and 6 were analyzed by direct
sequencing.All PCR ampliﬁcations were done with Taq DNApolymer-
ase in a Perkin-Elmer-Cetus DNA Thermal Cycler (Norwalk, CT).
Primers for PCR and sequencing were obtained from Integrated DNA
Technologies (Coralville, IA).
Detection of polymorphic alleles in genomic studies. Restriction
analyses were performed as previously described22 to determine the
genotype of the patient and his parents with respect to two polymor-
phisms that affect plasma levels of factor VII, the decanucleotide insert
in the 58 regulatory region and the Arg353Gln substitution in exon 8.
Brieﬂy, to detect the presence of the decanucleotide insert, a 431-bp
fragment spanning position 2323 (the insertion site for the decanucleo-
tide) was ampliﬁed by PCR from the genomic DNA of the patient and
his parents.Approximately 200 ng of PCR product was digested with 20
Uo fEcoR I (New England Biolabs, Beverly, MA) and then subjected to
electrophoresis on an 8% (wt/vol) polyacrylamide gel. The fragments
generated were 328 and 103 bp in the absence of the insert, or 328 and
113 bp in its presence. To detect the Arg353Gln substitution, a 239-bp
fragment of exon 8 surrounding the codon for amino acid 353 was
analyzed similarly. In this instance, the presence of the mutation
eliminates the only Msp I restriction site within the fragment. In the
absence of the mutation, Msp I digestion produced fragments of 186 and
53 bp.
Cell culture and transient transfection analysis. The human hepa-
toma cell line, HepG2 (ATCC HB 8065), was grown in minimal
essential medium supplemented with 10% fetal bovine serum, 1
mmol/L sodium pyruvate, 10 mmol/L HEPES pH 7.4, 2 mmol/L
glutamine, 100 U/mL penicillin G, and 100 mg/mL streptomycin, in a
5% CO2 humidiﬁed atmosphere at 37°C. Twenty hours before the start
of transfection, 1 3 106 HepG2 cells were seeded on replicate 60-mm
culture dishes. Cells were transfected with mixtures of reporter plasmid
DNAand an internal plasmid control to monitor transfection efficiency,
complexed with the LipofectAmine reagent (GIBCO-BRL, Gaithers-
burg, MD) according to the manufacturer’s recommendations. Each
transfection mixture contained 3 µg of the reporter plasmid and 1.5 µg
of pSV-b-galactosidase control plasmid (Promega Corp, Madison, WI).
After 16 hours of transfection, full growth media was given to the cells;
48 hours later, the culture media and cell lysates were assayed for
expression of human growth hormone (hGH) and b-galactosidase,
respectively. The media were assayed with the hGH assay kit (Nichols
Diagnostics Institute) according to the manufacturer’s directions. Con-
centrations of hGH were calculated from a standard curve ﬁtted with a
four parameter logistic model. The cell lysates were analyzed with a
colorimetric b-galactosidase assay kit (Promega Corp). Levels of
b-galactosidase in the samples were calculated by comparison with a
standard curve ﬁtted by linear regression using the least-squares
method. For each dish, the level of hGH expressed was normalized
using the corresponding level of b-galactosidase to correct for differ-
ences in transfection efficiencies. In each experiment, the pOGH
plasmid was also transfected into cells on control dishes; when
normalized for expression of b-galactosidase, the values for hGH
produced from the promoterless plasmid were subtracted from the
experimental values reported.
Electrophoretic mobility shift assays. HeLa cells were cultured as
described above, and nuclear extracts were prepared according to the
method of Dignam et al.28 The method of Bradford et al29 was used to
determine protein concentrations in the nuclear extracts. Complemen-
tary oligonucleotides extending from position 2108 to 284 of the
factor VII 58 ﬂanking region were annealed and end-labeled with
[g-32P]–adenosine triphosphate (ATP) using T4 polynucleotide kinase,
then puriﬁed using Sephadex G-50 spin columns (Boehringer Mann-
heim, Indianapolis, IN).19 For gel mobility shift assays, the procedure of
Chodosh et al30 was used with minor modiﬁcations. Ten micrograms of
HeLa nuclear extract, or 1 footprint unit of human recombinant
transcription factor Sp1 (Promega Corp), was incubated on ice for 10
minutes with 0.5 µg bovine serum albumin (BSA), 2.5 µg poly (dI.dC),
and 1 µg salmon sperm DNA(Sigma, St Louis, MO) in 20 µl of binding
buffer (25 mmol/L HEPES pH 7.6, 14 mmol/L KCl, 10% glycerol, 0.1
mmol/L EDTA, 0.75 mmol/L dithiothreitol, 5 mmol/L MgCl2). After
addition of 0.1 ng of radiolabeled double-stranded oligonucleotide
(approximately 100,000 cpm/ng) to the mixture, the reaction was
incubated on ice for an additional 20 minutes. In competition studies,
the unlabeled competitor oligonucleotide was added during the initial
incubation on ice. Following incubation, the reaction mixtures were
electrophoresed on a 5% (wt/vol) polyacrylamide gel and autoradio-
graphed. The oligonucleotide sequences used in the reactions were as
follows: wild-type, 58 2108 GTGTCCTCCCCTCCCCCATCCCTCT
38 284 and mutant 58 2108 GTGTCCTCCCCTCCGCCATCCCTCT
38 284; Sp1 consensus sequence (Promega Corp), 58ATTCGATC-
GGGGCGGGGCGAGC 38.
RESULTS
Patient. The patient is a 24-year-old Canadian man with a
bleeding diathesis, having plasma levels of both VII:Ag and
VII:C that are less than 1% of normal. He has a history of easy
bruising and was diagnosed with factorVII deﬁciency at age 11,
when he developed hemarthrosis of the left knee. Between the
ages of 12 and 15 years, he required infusions of fresh frozen
plasma at 2- to 3-month intervals for spontaneous bleeds within
his elbow and ankle joints. He was then placed on chronic
prophylaxis with factor VII concentrate (Immuno AG, Vienna,
Austria) three times per week with amelioration of the bleeding
diathesis. The patient’s parents do not have a bleeding disorder,
although both exhibit reduced plasma levels of VII:Ag and
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have normal factor VII levels (data not shown).
Identiﬁcation of mutations in the factor VII gene. Analysis
of the entire coding sequence and the intron/exon boundaries of
the patient’s factor VII gene revealed only the presence of two
previously described polymorphisms but no alterations suffi-
cient to account for his bleeding disorder. In exon 5,aCt oT
transition was observed at position 7880, which produces a
neutral dimorphism in the codon for His115.31 The only other
change in the coding sequence wasaGt oAsubstitution at
position 10976, which produces the Arg353Gln polymorphism
in exon 8. Subsequently, a 404-bp fragment of the 58 ﬂanking
region of the patient’s factorVII gene was examined and several
changes were found. These were the decanucleotide insert at
position 23 2 3 ,aCt oTsubstitution at position 2122, and a C
toGtransversionatposition294.Asmentioned,thedecanucleo-
tide insert frequently occurs in conjunction with theArg353Gln
polymorphism; these polymorphisms either alone or together
induce modest reductions in the plasma levels of factor
VII.18,20-22,32 The substitution at position 2122 has been ob-
served in an asymptomatic individual also carrying the deca-
nucleotide insert18 and therefore is not expected to contribute to
the patient’s phenotype.
The inheritance of these alterations in the factorVII gene was
conﬁrmed by sequence analysis of the parents (Table 1). Both
parents were found to be heterozygous for the transversion at
position294.Themotherwasheterozygousforthedecanucleo-
tide insert, the 2122 transition, and the Arg353Gln polymor-
phism.The father, like the patient, was homozygous for all three
changes, which may account for the observation that his levels
of VII:Ag and VII:C were slightly lower than the mother’s.
Characterization of the 294 C to G mutation. To analyze
the inﬂuence of the 294 C to G mutation on promoter function,
a fragment of the 58 ﬂanking region of the factor VII gene
extending from position 2185 to position 11 (the translational
start site) was prepared from the patient’s DNAand inserted into
the promoterless pOGH reporter plasmid as described in
Materials and Methods. A reporter plasmid containing the
wild-type sequence was similarly constructed. These plasmids
were then used to direct the expression of the hGH structural
gene in transient transfection experiments in HepG2 cells, a
human liver hepatoma cell line expressing factor VII and other
coagulation proteins.33 Figure 1 shows that the plasmid contain-
ing the mutant promoter fragment exhibited only 5.8 6 2.2% (1
SD) of the activity observed with the plasmid containing the
wild-type promoter fragment (n 5 14).
The 294 mutation occurs within the central hexanucleotide
core of an Sp1 binding site (CCTCCC to CCTCCG) in an area
shown by in vitro mutagenesis experiments to be important for
factor VII expression.17,18 Therefore, we examined by electro-
phoretic mobility shift assays the behavior of an oligonucleotide
containing the 294 C to G mutation with nuclear extracts from
HeLa cells (which contain abundant amounts of Sp1) and
compared it to that obtained with an oligonucleotide having the
wild-type sequence (Fig 2). The labeled wild-type oligonucleo-
tide formed four complexes with HeLa nuclear proteins desig-
nated Sp1, B, C, and D (lane 1). The presence of the ubiquitous
transcription factor Sp1 in the slowest-mobility complex has
been shown previously by the formation of a complex of
identical mobility between recombinant human Sp1 and the
wild-type factor VII sequence and by supershift experiments
with anti-Sp1 antibody.18 Binding between HeLa nuclear pro-
teins and the Sp1, B, and D complexes was speciﬁc as it could
be competed away by incubation with increasing amounts of
Table 1. Coagulation and Genotype Data in a Kindred
With Factor VII Deficiency
VII:C
(%)
VII:Ag
(%)
294 C
to G
2122 T
to C 2323 insert Arg353Gln
Patient ,1 ,1 1/11 / 11 / 11 / 1
Father 30 29 1/21 / 11 / 11 / 1
Mother 39 45 1/21 / 21 / 21 / 2
VII:C and VII:Ag results are expressed as percentage of a normal
plasma pool. PCR amplification, cloning, and sequencing (as detailed
in Materials and Methods) were used to identify the 29 4Ct oG
mutation, the 2122 T to C transition, and the 2323 decanucleotide
insert in both the patient and his parents, as well as the Arg353Gln
polymorphism in the patient. The 2323 insert and the Arg353Gln
polymorphism were also identified by PCR amplification and restric-
tion enzyme analysis as described in Materials and Methods. Presence
or absence of the sequence alteration on each allele is denoted by a 1
or 2 sign, respectively.
Fig 1. Functional analysis of the wild-type and mutant (29 4Ct o
G) factor VII promoters. One hundred eighty-six base pair fragments
of wild-type or mutant (MT94) human factor VII promoter sequence
were inserted into the hGH reporter vector and used to transiently
transfect HepG2 cells. The data were corrected as described in
Materials and Methods, and the level of hGH expression from
reporter plasmid containing the wild-type sequence was considered
100%. Relative to this, the level of hGH expression from the MT94
sequence was 5.8 6 2.2% (1 SD). The data shown were obtained from
three experiments in which a total of 14 dishes were transfected with
each expression vector.
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by equivalent amounts of unlabeled mutant oligonucleotide
(lanes 5 through 7). With the labeled mutant oligonucleotide, in
contrast, only complex C was formed (lane 8). This complex is
likely to be nonspeciﬁc because it cannot be competed away by
either the mutant or the wild-type oligonucleotide (lanes 9
through 14).
Further conﬁrmation that the patient’s mutation disrupted the
binding of Sp1 to the factor VII sequence is provided in Fig 3.
As shown in Fig 3A, a labeled consensus Sp1 oligonucleotide
bound a protein from HeLa nuclear extracts in the absence (lane
1) but not the presence (lane 2) of unlabeled Sp1 competitor
oligonucleotide. The wild-type factor VII oligonucleotide (lane
3) competed effectively for binding to this protein, whereas at
the same concentration the mutant factor VII oligonucleotide
(lane 4) did not. Additionally, as shown in Fig 3B, puriﬁed
recombinant human Sp1 bound directly not only to its consen-
sus Sp1 oligonucleotide (lane 1) but also to the wild-type factor
VII sequence (lane 2). However, the puriﬁed Sp1 did not bind
detectably to the mutant factor VII oligonucleotide (lane 3).
These data suggest that the 294 mutation prevents transcription
of the factor VII gene through disruption of binding by Sp1 and
other DNAbinding proteins to this region of the promoter.
DISCUSSION
We have identiﬁed a naturally occurring point mutation, a C
to G transversion at position 294 in the 58 ﬂanking region of the
human factor VII gene, which is responsible for factor VII
deﬁciency in a severely affected homozygous patient. The
patient also has two polymorphisms, the decanucleotide insert
at position 2323 and Arg353Gln, each of which diminishes
factor VII expression to a modest extent. However, these
polymorphisms cannot account for his phenotype, although it is
possible they contribute to a more severe bleeding diathesis
than might have been observed in their absence. The patient is
from a large French-Canadian family in which numerous
members have factor VII deﬁciency. In view of the known
consanguinity within the family,23,25 it is likely that homozygos-
ity for the C to G transversion at position 294 is responsible for
the factor VII deﬁciency observed in the other individuals of
this kindred. Indeed, we have investigated a second severely
affected individual from the same region, presumably a distant
relative of the proband, and conﬁrmed that he was homozygous
for the mutation at position 294 (data not shown).
In reporter gene assays performed with HepG2 cells, a
fragment of the mutant promoter extending from position 2185
to11exhibitedverylowactivitycomparedwiththecorrespond-
ing wild-type promoter fragment. In gel mobility shift assays,
introduction of the mutant sequence into an oligonucleotide
extending from position 2108 to 284 disrupted its binding to
several HeLa cell nuclear proteins including Sp1. Thus, the
reduced activity observed in reporter gene assays may be due to
disruption of binding not only to Sp1 but also to other
transcription factors, as yet unidentiﬁed. Numerous examples of
transcription factors that bind either in association with Sp1 or
at overlapping binding sites have been reported, including Ets,34
GATA-1,35 SREB-1,36 and H4TF1.37 Other factors such as Sp3
have been reported to compete with Sp1,38 whereas the speciﬁc
ratio of Sp1 to other transcription factors may also be important
for determination of promoter activity.39
Binding of oligonucleotides with the factor VII promoter
sequence to recombinant Sp1 protein was adversely affected by
Fig 2. Gel mobility shift as-
says show loss of nuclear pro-
tein binding with a mutant fac-
tor VII promoter sequence
(MT94) from a patient with se-
vere factor VII deficiency. A radi-
olabeled wild-type (WT) oligo-
nucleotide including the Sp1
binding site (2108 to 284 bp
before the translation start site)
in the human factor VII promoter
region showed binding to pro-
teins (arrows) from HeLa nuclear
extracts (lane 1). Specificity of
binding is shown by competition
with unlabeled WT oligonucleo-
tide sequence at 103, 1003, and
5003 concentrations (lanes 2, 3,
and 4) but not with an oligo-
nucleotidehavingthemutantse-
quence (lanes 5, 6, and 7). Lanes
8 through 14 show the lack of
binding of nuclear proteins by
complexes labeled Sp1, B, and D
to radiolabeled probe containing
the MT94 sequence.
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of wild-type promoter sequence competed away binding of a
radiolabeled Sp1 consensus oligonucleotide to Sp1 protein from
HeLa cell extracts. However, excess mutant factorVII sequence
did not, suggesting that the mutant oligonucleotide did not bind
Sp1 at all under these in vitro conditions. It should be noted that
direct binding of puriﬁed Sp1 to even the wild-type factor VII
sequence was weak compared with its binding to the consensus
Sp1 oligonucleotide. Within the 6-bp core Sp1 binding region
(CCGCCC), the only difference is the central residue,aGi nt h e
consensus but a T in the factor VII sequence. A previous study
investigating the effect of base changes within the core binding
region on the interaction with puriﬁed Sp1 found that altering
the central residue from G to T reduces Sp1 binding approxi-
mately threefold.40Additional reductions in binding may be due
to the effect of factor VII sequence ﬂanking the core binding
site. Greenberg et al 17 have also noted that the factor VII Sp1
site has lower affinity for puriﬁed Sp1 than does an Sp1 binding
site identiﬁed in the human metallothionein promoter. Weak
affinity of even the wild-type factor VII sequence for Sp1 may
A B
Fig 3. Interactions with an Sp1 consensus sequence and human Sp1 protein. (A) Unlabeled wild-type (WT) but not mutant (MT94) human
factor VII sequence competes for Sp1 binding with radiolabeled Sp1 consensus sequence. Lane 1 shows binding of radiolabeled Sp1 consensus
probe by HeLa nuclear extract in the absence of unlabeled competitor sequences. Lanes 2 through 4 show Sp1 consensus probe binding with
HeLa nuclear extract in the presence of 1,0003 concentrations of unlabeled competitor Sp1 consensus sequence (lane 2), WT factor VII sequence
(2108 to 284; lane 3), and MT factor VII–deficient patient sequence (2108 to 284; lane 4). (B) WT but not MT94 factor VII–deficient patient
sequence binds to the transcription factor Sp1. Binding of radiolabeled oligonucleotides with recombinant human Sp1 is shown with
radiolabeled Sp1 consensus sequence (lane 1) and WT factor VII sequence (lane 2) but not with MT factor VII–deficient patient sequence (lane 3).
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at 500 ng/mL, is the lowest of the vitamin-K–dependent
coagulation proteins.
Prior studies have shown that the region surrounding position
294 is essential for normal expression of the factor VII gene in
hepatoma cells.17,18 Greenberg et al17 performed mutational
analysis and showed that alteration of the nucleotides at
positions 298 and 2100 (CCCCTCCCCC to CACATCCCCC)
or of residues 292 to 296 inclusive (CCCCTCCCCC to
CCCCTAAAAA) decreased activity in reporter gene assays to
approximately 12% and 7% that of the wild-type sequence,
respectively. Pollak et al18 made point mutations at position
2100 (CCCCTCCCCC to CACCTCCCCC), position 294
(CCCCTCCCCC to CCCCTCCACC), and at both positions.
The 2100 alteration diminished speciﬁc binding of an oligo-
nucleotide spanning the region to both HeLa nuclear proteins
and puriﬁed recombinant Sp1 and reduced the level of expres-
sion in reporter gene assays to 35% of that observed with the
wild-typesequence.The294CtoAmutationandthecombined
mutations abolished nuclear protein binding and reduced re-
porter gene expression to 2% of wild-type. Interestingly, our
patient had nucleotide 294 mutated from C to G, conﬁrming
the importance of wild-type sequence in this region to factorVII
expression.
Naturally occurring mutations involving Sp1 binding sites
have recently been described in the promoters of several other
genes with variable effects on expression. For example, the
promoter of 5-lipoxygenase, a crucial enzyme in the synthesis
of leukotrienes, contains ﬁve tandem repeats of a strong
Sp1/Egr-1 consensus sequence. Deletions of one or two repeats,
or addition of a sixth, signiﬁcantly decreases activity in reporter
gene assays.41 Point mutations within the proximal Sp1 binding
site of the human low-density lipoprotein receptor promoter
decrease both Sp1 binding and receptor expression, inducing
moderate42orsevere43formsofheterozygousfamilialhypercho-
lesterolemia, depending on the particular base substitution.
Point mutations were also associated with increases in both Sp1
binding and protein expression in the g-hemoglobin gene,
resulting in persistence of fetal hemoglobin.44 Naturally occur-
ring mutations such as these, and the one described in this
report, validate in vitro analyses of gene regulation and provide
insight into mechanisms of human disease.
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